C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give C4 Therapeutics a “Moderate Buy” consensus: Five of seven analysts rate the stock a buy, while one rates it a hold and one a sell. The average 12-month price target is $7.75, well above the reported $4.21 opening price.
• The company exceeded quarterly expectations: C4 Therapeutics reported an adjusted loss of $0.18 per share versus the expected $0.23 loss, while revenue of $6.64 million surpassed the $4.00 million consensus estimate.
• C4 Therapeutics remains a high-risk, clinical-stage biotech: The stock has a negative net margin and return on equity, and Weiss Ratings reaffirmed a “sell (D-)” rating. Institutional investors own a substantial 78.81% of the company.

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $7.75.

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of C4 Therapeutics in a research note on Friday, July 17th.

C4 Therapeutics Stock Up 0.7%

Shares of NASDAQ:CCCC opened at $4.21 on Thursday. C4 Therapeutics has a 52-week low of $1.69 and a 52-week high of $5.17. The company has a market capitalization of $517.96 million, a P/E ratio of -4.21 and a beta of 2.91. The stock's fifty day simple moving average is $3.94 and its 200-day simple moving average is $3.25.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. The business had revenue of $6.64 million during the quarter, compared to the consensus estimate of $4.00 million. C4 Therapeutics had a negative net margin of 289.44% and a negative return on equity of 45.45%. On average, sell-side analysts anticipate that C4 Therapeutics will post -0.85 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Engineers Gate Manager LP raised its stake in shares of C4 Therapeutics by 49.9% in the 4th quarter. Engineers Gate Manager LP now owns 24,416 shares of the company's stock valued at $47,000 after acquiring an additional 8,130 shares during the period. SummitTX Capital L.P. bought a new stake in shares of C4 Therapeutics in the first quarter worth $28,000. CTC Alternative Strategies Ltd. bought a new stake in shares of C4 Therapeutics in the 1st quarter worth about $28,000. Man Group plc raised its stake in C4 Therapeutics by 15.0% during the third quarter. Man Group plc now owns 90,278 shares of the company's stock valued at $200,000 after buying an additional 11,791 shares in the last quarter. Finally, Zacks Investment Management acquired a new stake in shares of C4 Therapeutics during the 3rd quarter valued at approximately $29,000. Hedge funds and other institutional investors own 78.81% of the company's stock.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body's natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company's pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source